LQDA - Liquidia Corp
IEX Last Trade
11.87
0.180 1.516%
Share volume: 20,449
Last Updated: Thu 26 Dec 2024 08:30:24 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$11.69
0.18
1.54%
Fundamental analysis
21%
Profitability
0%
Dept financing
16%
Liquidity
75%
Performance
30%
Performance
5 Days
0.79%
1 Month
0.96%
3 Months
13.71%
6 Months
-6.41%
1 Year
-0.77%
2 Year
90.58%
Key data
Stock price
$11.87
DAY RANGE
$11.34 - $11.79
52 WEEK RANGE
$9.16 - $16.99
52 WEEK CHANGE
-$4.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Roger A. Jeffs
Region: US
Website: liquidia.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: liquidia.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
Recent news